Lucas P. Przymusinski

Representative of his experience are the following cases:

• Hernia Mesh Litigation: Co-national counsel for Medtronic in product liability litigation alleging injuries related to the use of hernia mesh

• Essure Litigation: Counsel for Bayer in product liability litigation alleging injuries related to the use of the Essure birth control device

• Eliquis Product Liability Litigation: National counsel for Bristol-Myers Squibb Co. and Pfizer Inc. in product liability litigation alleging that Eliquis causes bleeding
• In re Lipitor (Atorvastatin Calcium) Products Liability Litigation, MDL 2502 (D. S.C.): Counsel for Pfizer Inc. in product liability litigation alleging that Lipitor causes type 2 diabetes 
• In re Incretin Mimetics Products Liability Litigation, MDL 2452 (S.D. Cal.): National Counsel for Novo Nordisk Inc. in product liability litigation alleging that Victoza cause pancreatic cancer
• In re Chantix (Varenicline) Product Liability Litigation, MDL 2092 (N.D. Ala.): Counsel for Pfizer Inc. in product liability litigation involving Chantix, an aid to smoking cessation treatment
• In re Prempro Products Liability Litigation, MDL No. 1507 (E.D. Ark.): Counsel for Pfizer Inc. and Wyeth in product liability litigation involving claims that hormone therapy medication causes breast cancer
• In re Seroquel Products Liability Litigation, MDL 1769 (M.D. Fla.): Counsel for AstraZeneca in product liability litigation alleging that Seroquel causes type 2 diabetes

REPRESENTATIVE DECISIONS

• In re Incretin-Based Therapies Prod. Liab. Litig., No. 13-md-2452-AJB-MDD, 2021 WL 880316 (S.D. Cal. Mar. 9, 2021) (granting summary judgement in all MDL cases based on general causation and conflict preemption in litigation involving claims that diabetes medications cause pancreatic cancer)
• Utts v. Bristol-Myers Squibb Co., Case No. 16cv5668, 2017 WL 1906875 (S.D.N.Y May 8, 2017) aff’d Gibbons v. Bristol-Myers Squibb Co., 919 F.3d 699 (2d Cir. 2019) (dismissing plaintiffs’ claims with prejudice on federal preemption and adequacy of warnings grounds)
• Utts v. Bristol-Myers Squibb Co., 226 F.3d 166 (S.D.N.Y 2016) (dismissing plaintiffs’ design defect claims with prejudice on federal preemption grounds)
• In re Lipitor (Atorvastatin Calcium) Mktg., Sales Practices & Prod. Liab. Litig., No. MDL214MN02502RMG, 2016 WL 1251828, at *19 (D.S.C. Mar. 30, 2016) (excluding plaintiffs’ general causation experts’ testimony that Lipitor can cause diabetes at doses below 80 mg)
• In re Lipitor (Atorvastatin Calcium) Mktg., Sales Practices & Prod. Liab. Litig., 150 F. Supp. 3d 644 (D.S.C. 2015) (excluding plaintiff’s specific causation expert)
• In re Incretin-Based Therapies Prod. Liab. Litig., 142 F. Supp. 3d 1108, 1132 (S.D. Cal. 2015) (granting summary judgement in all MDL cases based on conflict preemption in litigation involving claims that diabetes medications cause pancreatic cancer)
• In re Byetta Cases, 2015 WL 7184655 (Cal. Super. Nov. 13, 2015) (granting summary judgement in all JCCP cases based on conflict preemption in litigation involving claims that diabetes medications cause pancreatic cancer)
• In re Prempro Prods. Liab. Litig., No. 4:03-CV-1507-WRW, 2010 WL 3447293 (E.D. Ark. Aug. 30, 2010) (excluding expert testimony that Premarin is capable of causing breast cancer)
• In re Prempro Prods. Liab. Litig., Nos. 4:03CV1507-WRW, 6:05CV06074, 2011 WL 178574 (W.D. Ark. Jan. 19, 2011) (excluding expert testimony that short-term use of Prempro is capable of causing breast cancer)
• Scaife v. AstraZeneca LP, 2009 WL 1610575 (Del. Super. June 9, 2009) (excluding expert testimony that Seroquel caused plaintiff to develop diabetes )
• Haller v. AstraZeneca Pharm. LP, 598 F. Supp. 2d 1271 (M.D. Fla. 2009) (excluding expert testimony that Seroquel caused plaintiff to develop diabetes )
• Guinn v. AstraZeneca Pharm. LP, 598 F. Supp. 2d 1239 (M.D. Fla. 2009), aff'd, 602 F.3d 1245 (11th Cir. 2010) (excluding expert testimony that Seroquel caused plaintiff to develop diabetes)

• Co-author, "Cannabis Mass Tort Litigation: What’s on the Horizon?" American Bar Association, April 7, 2023

2019 Law360 articles and DLA Piper client alerts: 

• In Albrecht, US Supreme Court narrows implied preemption of failure-to-warn claims, finds preemption is legal issue for judge, not jury, by Ilana Eisenstein, Loren Brown, Lucas Przymusinski, Stan Panikowski and Adam Pierson, May 2019
• Significant preemption win for Bristol-Myers-Squibb and Pfizer in Eliquis product liability multi-district litigation by Matt Holian and Lucas Przymusinski, March 2019
• Supreme Court hears oral argument in Fosamax: key takeaways by Ilana Eisenstein, Loren Brown, Lucas Przymusinski and Stan Panikowski, January 2019